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Abstract
Background: Apolipoprotein C3 (APOC3) is a component of triglyceride-rich lipoproteins, and APOC3 rs2854116
and rs2854117 polymorphisms have been associated with non-alcoholic fatty liver disease, hypertriglyceridaemia,
and insulin-resistance.
Objective: To determine if the APOC3 variants alter the susceptibility of obese subjects to develop liver damage,
hypertrigliceridaemia, and insulin-resistance.
Methods: The study was carried out on 585 unrelated obese Italians (median body mass index BMI = 41 kg/m
2)
who were genotyped for the rs2854116 and rs2854117 variants. All participants underwent oral glucose tolerance
tests (OGTT), with measurement of glucose, insulin, lipid parameters. Indices of insulin-resistance (HOMA and ISI)
were calculated. Alanine transaminase (ALT) and aspartate transaminase (AST) were used as markers of liver injury.
Results: The study subjects were divided into two groups: those homozygous for the wild-type alleles at both
SNPs (-482C and -455T alleles) and those who were carriers of at least one variant allele or both (-482T, -455C or
both). Also each SNP was analysed independently. No significant differences were found in ALT and AST levels and
in the lipid profile between the two groups. Insulin concentrations, glucose tolerance and insulin sensitivity were
similar in the two groups.
Conclusion: We did not identify any significant association between APOC3 polymorphisms and fatty liver disease,
lipids, and insulin-resistance in obese subjects, thus not confirming the suggested role of these APOC3 gene
sequence variants.
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Background
Non-alcoholic fatty liver disease (NAFLD) is a multifac-
torial disorder arising from the interplay between
genetic susceptibility and environmental influences. A
large body of evidence shows that NAFLD is highly
related to obesity and its metabolic consequences such
as insulin resistance and dyslipidaemia [1]. In addition
to altering metabolic risk, hepatic steatosis is also asso-
ciated with significant liver disease in some patients. As
many as 10-20% of patients with NAFLD develop stea-
tohepatitis [1] and approximately 5% proceed to liver
cirrhosis within 10 years of diagnosis [2].
The hallmark of hepatic steatosis is the presence of
triglycerides (TGs) stored as large lipid droplets in the
cytoplasm of hepatocytes. Hepatic steatosis strongly
associates with hypertriglyceridaemia and low high den-
sity lipoprotein cholesterol (HDL-C) levels, two common
features of the metabolic syndrome. The vast majority of
individuals with hepatic steatosis have elevated alanine
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used as a surrogate index of NAFLD [3]. Hypertriglycer-
idaemia is also strongly associated with elevated transa-
minases, in particular ALT [4].
Recently, it has been proposed that two sequence var-
iants in the promoter of the gene encoding human apo-
lipoprotein C3 (APOC3, rs2854116 and rs2854117) were
associated with hypertriglyceridaemia, nonalcoholic fatty
liver disease and insulin resistance in lean individuals of
South Asian descent [5]. Apolipoprotein C3 is a small
exchangeable apolipoprotein (79 amino acids) and one
of the major constituents of plasma very low density
lipoprotein (VLDL), chylomicrons and HDL-C [6]. Ele-
vated plasma apolipoprotein C3 levels are positively cor-
related with plasma triacylglycerol concentrations in
hypertriglyceridemic subjects [7]. Apolipoprotein C3
inhibits the hydrolysis of TG-rich particles by lipopro-
tein lipase and their apoE-mediated hepatic uptake [8,9].
Experimental studies have demonstrated that overex-
pression of APOC3 causes delayed clearance of TG-rich
lipoproteins from plasma, resulting in hypertriglyceri-
daemia [6]. The suggested mechanism involves therefore
increased plasma concentrations of apolipoprotein C3,
which in turn inhibits lipoprotein lipase and triglyceride
clearance, and consequently increases fasting and post-
prandial hypertriglyceridaemia.
More recent data do not confirm the association
between the rs2854116 and rs2854117 variants in
APOC3 and either hepatic triglyceride content or insulin
resistance or fasting triglyceride levels in a large popula-
tion-based (n = 2,239) study comprising three different
ethnic groups (European Americans, African Americans,
and Hispanics) [10]. In particular, authors failed to repli-
cate the association between the APOC3 SNPs and
hepatic triglyceride content measured by magnetic reso-
nance spectroscopy [10].
We have previously observed that excess of body mass
exacerbates the association of the Patatin like phospholi-
pase domain containing C 3 protein (PNPLA3) I148M
variant with hepatic fat and liver damage, with increased
circulating ALT levels, in a cohort of severly obese Ita-
lian adults and children [11,12]. The role of BMI in
increasing ALT levels and the risk of NAFLD has been
recognized for several years [13]. In this contex we
hypothize that obesity would expose the association
between the APOC3 variants and liver parameters, insu-
lin-resistance and/or lipid levels.
We hence genotyped a large cohort (n = 585) of Ita-
lian obese subjects (mean body mass index (BMI) = 42
±8k g / m
2) for the two sequence variants in APOC3
gene promoter (rs2854116 [-455 T/C] and rs2854117
[-482 C/T]), aiming to evaluate the association between
APOC3 variants and alanine transaminase levels,
triglyceride levels and insulin resistance, in subjects with
a higher predisposition to an altered metabolic profile.
Methods
Patient recruitment
A total of 585 consecutive unrelated obese (BMI ≥ 30
kg/m
2) Caucasians were recruited from the Day-Hospital
of the Department of Clinical Sciences, University of
Rome “La Sapienza”. They underwent complete medical
evaluation and a standard 75 g oral glucose tolerance
test (OGTT) with measurements of glucose and insulin
at baseline and after 30, 60, 90, 120 minutes. Individuals
with daily ethanol consumption of greater than 40
grams or a history of viral hepatitis were excluded from
the study. Metabolic Syndrome was classified according
to NCEP ATP-III 2004 criteria. In the recruitment of
our cohort alcohol consumption was classified as a cate-
gorical variable (> or < 40gr) based on the International
Center for Alcohol Policies (ICAP, http://www.icap.org/
). This organization reports the recommended alcohol
intake for Italy (as stated by the Italian Ministry for
Agriculture & Forestry and National Institute for Food
and Nutrition) to be < 40 g/day with no differences
between men and women (http://www.icap.org/Table/
InternationalDrinkingGuidelines).
In a subgroup (n = 170) of our study population ultra-
sound imaging for liver fat content was available. Ultra-
sound scanning was performed by the same operator,
who was unaware of the aims of the study and blinded
to laboratory values. Liver steatosis was assessed as pre-
sent or absent. Steatosis was determined on the basis of
abnormally intense, high-level echoes arising from the
hepatic parenchyma, liver-kidney differences in echo
amplitude, echo penetration into deep portions of the
liver and clarity of vascular structures.
Participants were not on glucose lowering drugs. Also
patients in lipid-lowering treatment were excluded from
the study. All individuals provided informed consent
prior to inclusion in the study. Research carried out on
humans complied with the Helsinki Declaration. The
study was approved by the University research ethics
committee.
Biochemistry
Glucose, insulin, cholesterol, HDL-choleserol and trigly-
cerides (TGs) were measured as previously described
[14], after an overnight fast. Glucose leveles below 100
mg/dl, HDL > 40 mg/dl for men and > 50 mg/dl for
women, triglycerides < 150 mg/dl were taken as normal
limits.
Serum alanine (ALT) and aspartate aminotransferase
(AST) levels in fasting subjects were assayed using a
Hitachi 737 analyzer (Boehringer-Mannheim Diagnos-
tics, Indianapolis, IN). HOMA-IR and Insulin Sensitivity
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by Matthews et al. and Matsuda et al. [15,16].
Genotyping assay
We developed fluorogenic 5’-nucleotidase assays for
APOC3 rs2854117 gene polymorphism. The assay was
performed using the TaqMan C7241_10 assay (Applied
Biosystems, Foster City, CA) in a total volume of 2.7 μl
on a 7900HT Fast Real-Time PCR instrument (Applied
Biosystems). The plate was run at 95°C for 10 minutes,
92°C for 15 seconds then 60°C for 1 minute for 40 cycles.
The APOC3 rs2854116 gene variant was assayed by
the restriction fragment length polymorphism (RFLP)
technique. A 497-bp fragment was amplified and enzy-
matically restricted using BtsCI (New England Biolabs,
Ipswich, MA, USA). The resulted enzyme-digested frag-
ments of the PCR products were fractionated on 3.5%
agarose gels, stained with ethidium bromide, and visua-
lized with an imaging system (Amersham-Pharmacia
Biosciences).
Allele frequencies were in Hardy-Weinberg
Equilibrium.
Statistical analysis
Categorical variable distributions were compared by the
Pearson c2. Differences between continuous variables
a c r o s st h eg e n o t y p ec l a s s e sw e r ee v a l u a t e db yA N O V A
including gender, age and BMI as covariates. Skewed
variables wer logharitmically transformed prior to enter-
ing the analyses. The study had a power of 80% at an
error rate of 5% to allow detection of differences in tri-
glycerides or ALT/AST levels (the main variables asso-
ciated with APOC3 gene [5]). Linkage disequilibrium
between the rs2854116 and rs2854117 SNPs was
assessed by calculating the disequilibrium statistics Δ
[17] and D’ [18]. The sign of D’ (positive or negative)
depends on the arbitrary choice of the alleles paired at
the two loci, and indicates whether the same or opposite
allelic association is present. All statistical analyses were
performed with SPSS 17.0 statistical package.
Results
Clinical characteristics of the study subjects are reported
in Table 1. All subjects were obese (median BMI 41 kg/
m
2, interquartile range 36.5-47.5) Mean blood pressure,
median lipid and glucose parameters were within normal
ranges. Only insulin resistance indices (HOMA-IR and
ISI) were indicative of reduced insulin sensitivity, as
would be expected in obese subjects. Looking at subjects
with an altered lipid profile, 27% had high TGs. Low
HDL was present in 32.7% of males and 50.6% of females,
and 16% had both, high TGs and low HDLs, an associa-
tion also defined as the atherogenic dyslipidaemia. Med-
ian transaminase levels were also within normal limits
(using < 40 U/L as cut-off) (Table 1).
The allele frequencies of the rs2854117 (-482T) and
rs2854116 (-455C) APOC3 alleles were 0.26 and 0.37,
respectively, similar to previously reported frequencies
[10]. Linkage disequilibrium between the two SNPs by
the disequilibrium statistics Δ and D’ showed a very
strong linkage disequilibrium (D’ = -0.97, Δ = 0.43,
P < 0.0001).
As previously analyzed [5] we first divided the study
subjects into two groups: those who were homozygous
for the wild-type alleles at both SNPs (-482C and -455T
alleles) and those who were carriers of at least one allele
or both (-482T, -455C or both). The rationale for this is
the association between the variant alleles at rs2854116
(T-455C) and at rs2854117 (C-482T) have been shown
to be independently associated with higher APOC3
levels [19]. We next analyzed the two variants separately
in our study cohort.
The clinical parameters of the study subjects, stratified
by genotype classes are shown in Table 2. There were
no significant differences between the two groups in
plasma concentration of ALT and aspartate transami-
nase (AST) levels, total cholesterol, HDL-and low den-
sity lipoprotein (LDL)-cholesterol, and circulating
triglycerides (Table 2).
We also tested for an association with surrogate
indices of insulin resistance (homeostatic model assess-
ment of insulin resistance and Matsuda Insulin Sensitiv-
ity Index), but no differences were found in the 340
variant-allele carriers compared to the wild-type homo-
zygote subjects (Table 2). Glucose and insulin levels
Table 1 Clinical characteristics of study subjects
N 585
Women/Men 422/163
Age (yr) 42 (31-52)
Body Mass Index (Kg/m
2)
a 41 (36.5-47.5)
SBP (mm/Hg) 130 (120-140)
DBP (mm/Hg) 80 (80-90)
Triglycerides (mg/dL) 113 (81-157.2)
Total Cholesterol (mg/dL) 200 (178-227.1)
HDL Cholesterol (mg/dL) Male: 43 (38.1-49.1)
Female: 50 (44-58.5)
LDL Cholesterol (mg/dL) 122 (103.5-146.2)
ALT (U/L) 28 (20.5-43)
AST (U/L) 20 (16-26)
Fasting blood glucose (mg/dL) 90 (82-99)
Fasting blood insulin (μU/mL) 24 (16.3-35)
HOMA-IR (U) 5.1 (3.4-8.4)
ISI (U) 2.1 (1.4-3.4)
Type 2 diabetes n (%) 40 (6.8)
a BMI was calculated as body weight (kg)/height (m
2). Values are medians and
interquartile ranges. Abbreviations: SBP, systolic blood pressure; DBP, diastolic
blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein;
ALT, alanine transaminase; AST, aspartate transaminase; HOMA-IR, homeostatic
model assessment of insulin resistance; ISI, insulin sensitivity index.
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cose tolerance test (Figure 1).
To confirm the lack of effects of the two SNPs, we eval-
uated the prevalence of variant alleles in subjects with
normal and pathological serum levels of ALT (defined as
> 40 U/L). In individuals with elevated levels of ALT, we
found no significant difference in the variant allele fre-
quency 40.6% vs 59.4% (wild type homozygotes vs var-
iant-allele carriers respectively, P = 0.918) (Table 3).
Furthermore, we investigated the prevalence of variant
alleles by comparing the low and the high ends of
HOMA-IR index distribution. No significant difference
in the variant allele frequency 41.4% vs 58.6% (wild type
homozygotes vs variant-allele carries respectively) in the
lowest quartile of HOMA-IR, and 36.6% vs. 63.4% (wild
type homozygotes vs variant-allele carries respectively) in
the highest quartile of HOMA-IR (P = 0.512) (Table 3).
We then examined the three genotypes in each SNP
independently. Neither the rs2854117 nor the rs2854116
APOC3 polymorphism associated with any of the para-
meters tested (data not shown) confirming the lack of
effect of the variants. Further anlayses with the haplo-
types groups derived from rs2854117 and rs2854116
APOC3 polymorphisms confirmed the lack of associa-
tion of the APOC3 variants with clinical and metabolic
parameters (data not shown).
To exclude that the presence of insulin-resistance or
obesity could mask the possible effects of the APOC3
SNPs, we stratified our subjects on the basis of their
insulin-resistance indices, insulin levels, or grade of obe-
sity. When we selected the carriers (n = 78) of the
Table 2 Clinical Features of the Study Participants in APOC3 Wild-Type Homozygotes (C-482 and T-455) and Carriers
of Variant Alleles (C-482T, T-455C or both)
Wild Type Homozygotes
(n = 239)
Variant-Allele Carriers
(n = 346)
p value
a
Linear regression Mann-Whitney Test
ALT (U/L) 27 (20-41.5) 29 (21-44) 0.102 0.125
AST (U/L) 19 (16-25) 20 (16-26.7) 0.190 0.366
Triglycerides (mg/dL) 115 (79.9-158.1) 112 (81.6-157) 0.575 0.919
Total Cholesterol (mg/dL) 200 (178.3-229) 200 (178-224.4) 0.726 0.698
HDL Cholesterol (mg/dL) 48 (42.4-56) 48 (41-56.5) 0.617 0.509
LDL Cholesterol (mg/dL) 122 (105.2-149.5) 125 (100.3-145.3) 0.758 0.711
Age (yr) 42 (33-53) 42 (30-51) 0.200 0.261
Body Mass Index (Kg/m
2) 41 (37-47.3) 41 (36-47.7) 0.813 0.575
Fasting blood glucose (mg/dL) 90 (83-98) 89 (81-100) 0.985 0.697
Fasting blood insulin (μU/mL) 23 (15.4-33) 25 (16.6-36.6) 0.371 0.294
HOMA-IR (U) 5 (3.4-7.7) 5.1 (3.4-8.8) 0.341 0.361
ISI (U) 2.1 (1.4-3.6) 2.1 (1.3-3.3) 0.925 0.609
a P values were calculated using linear regression model including age, BMI and sex. Fasting blood glucose, fasting blood insulin, HOMA-IR and ISI were log-
transformed before being entered into the model. Values are medians and interquartile ranges.
Figure 1 Carriers of APOC3 variant alleles (-482T, -455C or
both) were compared with homozygous for the wild-type
alleles at both SNPs (-482C and -455T alleles) for glucose and
insulin measurements during oral glucose tolerance test
(OGTT). The study cohort underwent OGTT (75 g) test and glucose
and insulin were measured baseline (0) and at 30, 60, 90 and 120
min after the administration of glucose. (A) Median glucose and (B)
insulin in individuals stratified by the genotypes. No statistical
differences were found in either insulin or glucose at different time
points in the two groups. P-values were calculated by linear
regression (all P-values = NS), including age, gender and body mass
index (BMI) as covariates in the model.
Table 3 Comparison of prevalence of variant alleles
estimated by chi-square analyses in subgroups
Wild Type
Homozygotes
n (%)
Variant-Allele
Carriers
n (%)
p
value
a
ALT ≥ 40 (U/L) 54 (40.6) 79 (59.4) 0.918
ALT < 40 (U/L) 145 (41.4) 205 (58.6)
75
th HOMA-IR
(U)
48 (36.6) 83 (63.4) 0.512
25
th HOMA-IR
(U)
55 (41.4) 78 (58.6)
Liver steatosis 49 (42.6) 66 (57.4) 0.869
No liver
steatosis
25 (45.5) 30 (54.5)
a P values were calculated using the Pearson c2. Abbreviations: ALT, alanine
transaminase; HOMA-IR, homeostatic model assessment of insulin resistance.
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sitive (lowest quartile of HOMA-IR), we did not observe
any effect on transaminases and on lipoprotein levels
(data not shown). Similar negative results were observed
when subjects were selected from those with the highest
(34.8 μU/mL) levels of plasma insulin. Among our
cohort of 585 obese individuals 53% (n = 311, BMI > 40
kg/m
2) were morbidly obese and 47% were only obese
(n = 274) with BMI ranging between 30 and 40 kg/m
2.
When we performed the same genetic analyses in the
two separate groups, we did not find any difference in
mean levels of ALT and/or AST, triglycerides and insu-
lin resistance parameters. No differences were found
when the obese subjects were stratified by gender (data
not shown). Also, no differences in any parameter were
observed between carriers of the APOC3 variants and
non-carriers when we analysed in our cohort only the
subjects with the Metabolic Syndrome (n. = 261) (data
not shown).
Finally, To account for other possible confounding
factors such as use of non-steroidal anti-inflammatory
(NSAIDs) and antihypertensive drugs, we looked at
transaminase levels in individuals treated with these
drugs and untreated patients. No differences in ALT/
AST levels were observed for both classes of drugs, nor
the genetic study was modified when a separate analyses
excluding those under NSAIDs/antipypertensive treat-
ment was performed (data not shown).
A subgroup (n = 170) of our study population was
analyzed for liver fat content by ultrasound scanning.
We observed a frequency of 68% of steatosis. When, we
compared ALT levels between individuals with no liver
damage vs patients with diagnosis of steatosis we
observed a significant increase in transaminase levels
(27.3 ± 14.5 vs 37 ± 26.7 U/L respectively, P = 0.009)
with a significant correlation (p < 0.005), confirming ala-
nine transaminase as a reliable marker of liver injury in
our population. When we performed separate analyses
in this subset of individuals, we found very similar
r e s u l t sa so b s e r v e di nt h ew h o l es t u d i e dp o p u l a t i o n .
There were no significant differences between the two
genotype classes in plasma concentration of ALT and
AST levels, presence or absence of steatosis, total cho-
lesterol, HDL-and low density lipoprotein (LDL)-choles-
terol, circulating triglycerides, surrogate indices of
insulin resistance (homeostatic model assessment of
insulin resistance and Matsuda Insulin Sensitivity
Index), glucose and insulin levels (data not shown).
Furthermore, we found no significant difference in the
variant allele frequency (42.6% wild type homozygotes vs
57.4% variant-allele carries respectively, P = 0.869) in
the subjects with echographic diagnosis of liver steatosis
(Table 3).
Discussion
Genetic susceptibility may be influenced by obesity sta-
tus. Previous studies have described modulation of the
PPARG Pro12Ala SNP by BMI in type 2 diabetes
[20,21]. Also, we have recently observed that excess of
body mass exacerbates the association of the PNPLA3
I148M variant with hepatic fat and liver damage, with
increased circulating ALT levels, in a cohort of Italian
severe obese subjects (mean body mass index (BMI) =
41 kg/m
2) [11]. The association between the PNPLA3
variant and liver damage was also confirmed in obese
children [12].
Similarly, in this study we performed genetic associa-
tion analyses in a cohort of Italian obese subjects, to
test whether obesity would expose the association
between the APOC3 rs2854116 and rs2854117 variants
and ALT levels as surrogate markers of hepatic steatosis.
Also triglyceride levels and indices of insulin-resistance
were analyzed for association.
We did not observe any significant difference between
carriers of the variants and wild-type homozygote sub-
jects in plasma concentrations of ALT and/or AST, thus
suggesting that the two SNPs are not influencing fatty
liver disease in our obese cohort. Although transami-
nases are only surrogate indices of fatty liver disease, in
many epidemiological studies ALT, in particular, has
been used as a marker of liver fat accumulation
[4,22,23] and is commonly used in clinical practice as
marker of steatohepatitis [24]. Finally, ALT levels
strongly correlate with BMI, but increased ALT in over-
weight persons should not be interpreted as nonspecific
biochemical interference and corresponds to typical his-
topathologic lesions [25].
In addition, we did not find any association between
the APOC3 SNPs and circulating triglycerides, total
cholesterol, HDL-and LDL-cholesterol. Petersen et al.
[5] found that fasting plasma triglyceride levels were
approximately 60% higher in the carriers of the variant
alleles in lean Asian Indian men. However, Richart and
colleagues recently found no relationship between
APOC3 mRNA expression and triglycerides content in
the livers of 44 morbidly obese women of European des-
cent. Also they did not find any association between
gene expression and plasma triglyceride concentrations
or insulin-resistance index determined by homeostasis
model assessment [26]. Very recent data from a large
multiethnic population in which hepatic triglyceride
content was measured by magnetic sprectoscopy did not
replicate the association between these two variants in
APOC3 and either hepatic triglycerides content or insu-
lin resistance [10]. These results are consistent with the
lack of association in transaminase levels in obese car-
riers that we observe in this study.
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scriptionally downregulated by insulin [27]. Furthermore
it was shown that, unlike the wild-type promoter, the
promoter containing variants at positions -455 and -482
remains constitutively active over a high range of insulin
concentrations with a reduced affinity for the nuclear
transcription factors mediating the insulin response,
thus inducing insulin resistance at the gene level [19]. It
could be argued that, in the context of the insulin resis-
tance associated with obesity the APOC3 variants are
unable to induce further actions on lipid levels. How-
ever, we should point out that when we looked only at
carriers of the variant alleles with normal insulin sensi-
tivity, we did not observe any association with indices of
fatty liver disease and lipid levels, suggesting that also in
this state the APOC3 variants are not influencing TG
concentrations.
One limitation of our study is that we do not have
direct measurement of hepatic fat content (echography
or MRI) in all our study subjects. However, as discussed
above, ALT is a well established variable to asses liver
damage [4,22,23] and it is commonly used in clinical
practice as a marker of steatohepatitis [24,28,29].
Furthermore, when we compared in a subset of subjects
ALT levels between individuals with no liver damage vs
patients with diagnosis of steatosis by echography, we
observed a significant increase in transaminase levels
confirming alanine transaminase as a reliable marker of
liver injury in our population. The genetic analyses in
this subgroup confirmed the lack of association of the
APC3 variants. Another possible limitation relates to the
alcohol consumption limits proposed by WHO, which is
different according to gender. However, in the recruit-
ment of our cohort the alcohol consumption was classi-
fied as > or < 40 gr based on the International Center
for Alcohol Policies (ICAP), which does not establish
any difference between men and women in the Italian
population.
Another point to bear in mind is that all studies on
APOC3 have been performed in different ethnic groups
and in different countries with large differences in diet-
ary habits. However, the lack of association of APOC3
variants has been now consistently reported in European
American, African American, and Hispanic populations.
Conclusions
In summary, no significant association between the
rs2854116 and rs2854117 genetic variants in APOC3
gene and impairment in markers of fatty liver disease,
l i p i dp r o f i l ea n di n s u l i n - r e s i s t a n c ew a so b s e r v e di no u r
Italian obese population, thus not confirming the sug-
gested role [5] of these APOC3 gene sequence variants.
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